rociletinib and Diarrhea

In 2015, the FDA approved an unprecedented number of new therapies for non-small cell lung cancer (NSCLC), among them therapies addressing specific genomic tumor subsets in the setting of development of resistance to first-line targeted therapy. Osimertinib (Tagrisso, formerly AZD9291; AstraZeneca) is indicated for patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy. It received breakthrough therapy designation, priority review status, and accelerated approval from the FDA. Clin Cancer Res; 23(3); 618-22. ©2016 AACR.

Topics: Acrylamides; Adenosine Triphosphate; Aniline Compounds; Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Disease Progression; Drug Eruptions; Drug Resistance, Neoplasm; ErbB Receptors; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Molecular Targeted Therapy; Mutation, Missense; Neoplasm Proteins; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Single-Blind Method